TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25756517

Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Methotrexate plus 5-Fluorouracil (5-FU)
Number of subjects: 117
Study: 22119148

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Bifidobacterium breve 99 and Propionibacterium freudenreichii JS)
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 20186295

Group type: EXPERIMENTAL
Intervention: Ketamine 2 mg.kg(‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol 0.5 mg.kg(‐1)
Number of subjects: 30
Study: 17663102

Group type: EXPERIMENTAL
Intervention: Puncturing with needles in alignment at the hairline region
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral administration of Duxil (control group)
Number of subjects: 120
Study: 16135001

Group type: EXPERIMENTAL
Intervention: Specific oral tolerance induction (SOTI) treatment with a maximum dose of 250 ml cow's milk or 4.5 g lyophilized hen's egg protein; daily maintenance dose of 100 ml cow's milk or 2.5 g hen's egg protein
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: SOTI treatment
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Regular allergen intake
Number of subjects: 3
Study: 12406811

Group type: EXPERIMENTAL
Intervention: HIV voluntary counseling and testing (VCT)
Number of subjects: 1634
Study: 10439984

Group type: EXPERIMENTAL
Intervention: GP input into discharge planning (test group)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Standard discharge planning (control group)
Number of subjects: 364
Study: 7782117

Group type: EXPERIMENTAL
Intervention: Roxithromycin 300 mg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clarithromycin and Azithromycin
Number of subjects: 0
Study: 2222246

Group type: EXPERIMENTAL
Intervention: GM-1 treatment (100 mg by daily intramuscular injection for 12 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 348131

Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 30829777

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A (BTX‐A) injection
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (sterile normal saline)
Number of subjects: 19
Study: 30623901

Group type: EXPERIMENTAL
Intervention: Acellular human dermal allograft (MegaDerm®)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Autologous tragal perichondrium
Number of subjects: 60
Study: 26346640

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 37
Study: 24443385

Group type: EXPERIMENTAL
Intervention: Social connection messages
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social change messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-targets
Number of subjects: 0
Study: 22759327

Group type: EXPERIMENTAL
Intervention: Lafutidine at 10 mg t.i.d., amoxicillin at 750 mg b.i.d., and metronidazole at 250 mg b.i.d. (LFT-AM)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Rabeprazole at 10 mg b.i.d., amoxicillin at 750 mg b.i.d., and metronidazole at 250 mg b.i.d. (RPZ-AM)
Number of subjects: 52
Study: 19339001

Group type: EXPERIMENTAL
Intervention: Mixed (M) group: rFSH and cetrorelix mixed immediately before administration
Number of subjects: 140

Group type: COMPARATOR
Intervention: Separate (S) group: rFSH and cetrorelix administered separately
Number of subjects: 140
Study: 18844696

Group type: EXPERIMENTAL
Intervention: 1000 mg CP‐481715 TID
Number of subjects: 40

Group type: COMPARATOR
Intervention: 3000 mg CP‐481715 QD
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (TID and QD)
Number of subjects: 40
Study: 15964147

Group type: EXPERIMENTAL
Intervention: Apomorphine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clonidine and Apomorphine
Number of subjects: 50
Study: 11923586

Group type: EXPERIMENTAL
Intervention: Metadoxine (900 mg intravenous)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 10373342

Group type: EXPERIMENTAL
Intervention: biosynthetic GH 2 IU/m2 s.c. daily (n=13)
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo (n=11)
Number of subjects: 24
Study: 7756472

Group type: EXPERIMENTAL
Intervention: Dapsone/pyrimethamine (200/75 mg once weekly)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Aerosolized pentamidine (300 mg every 4 weeks)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Dapsone/pyrimethamine (in tolerant patients)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Dapsone/pyrimethamine and aerosolized pentamidine
Number of subjects: 533
Study: 2184811

Group type: EXPERIMENTAL
Intervention: Heparinized normal saline (HNS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Heparinized 5% dextrose water (HD5W)
Number of subjects: 60
Study: 6158933

Group type: EXPERIMENTAL
Intervention: Fibroblast interferon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30690418

Group type: EXPERIMENTAL
Intervention: Fixel-based analysis of diffusion MRI data
Number of subjects: 221

Group type: COMPARATOR
Intervention: Conventional fractional anisotropy analysis
Number of subjects: 221
Study: 27820729

Group type: EXPERIMENTAL
Intervention: Dance
Number of subjects: 26
Study: 25886354

Group type: EXPERIMENTAL
Intervention: Participatory physical and psychosocial intervention
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group receiving the intervention in year two
Number of subjects: 400
Study: 23899008

Group type: EXPERIMENTAL
Intervention: Yoga intervention (12 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 41
Study: 21273172

Group type: EXPERIMENTAL
Intervention: Continued treatment with lenalidomide and dexamethasone
Number of subjects: 212

Group type: COMPARATOR
Intervention: Discontinued therapy without progression (control group)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Continued lenalidomide treatment
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Each additional cycle of lenalidomide
Number of subjects: 212
Study: 19586958

Group type: EXPERIMENTAL
Intervention: Ultrasonographic-guided interscalene brachial plexus blockade (ISB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anaesthesia (GA)
Number of subjects: 40
Study: 18410864

Group type: EXPERIMENTAL
Intervention: lornoxicam 8 mg (twice daily)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg (twice daily)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ketoprofen 100 mg (twice daily)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: dipyrone 1 g (three times daily)
Number of subjects: 200

Group type: COMPARATOR
Intervention: placebo (twice daily)
Number of subjects: 200
Study: 15980656

Group type: EXPERIMENTAL
Intervention: Self-generated strategy
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Number-consonant mnemonic strategy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (non-practice)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Learning speed (fast learners)
Number of subjects: 60
Study: 11884911

Group type: EXPERIMENTAL
Intervention: Conservative treatment
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 53
Study: 10450449

Group type: EXPERIMENTAL
Intervention: Albendazole (single 400 mg dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mebendazole (single 500 mg dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pyrantel (single dose 12.5 mg/kg bodyweight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8572849

Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg/day)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg/day)
Number of subjects: 54
Study: 2467982

Group type: EXPERIMENTAL
Intervention: Ranitidine, 150 mg twice a day for 4 days
Number of subjects: 13
Study: 407607

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: l-amphetamine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: methylphenidate
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study: 30638766

Group type: EXPERIMENTAL
Intervention: Modified pre-test genetic counseling (20-minute presentation via email prior to telephone call)
Number of subjects: 382

Group type: COMPARATOR
Intervention: Traditional pre-test genetic counseling (in-person)
Number of subjects: 382
Study: 28315319

Group type: EXPERIMENTAL
Intervention: Subcutaneous IFN‐α2a
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids
Number of subjects: 48

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 48
Study: 25788164

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 1190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1190
Study: 23266342

Group type: EXPERIMENTAL
Intervention: Intramuscular MVA85A
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intradermal MVA85A
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of both routes
Number of subjects: 24
Study: 21923715

Group type: EXPERIMENTAL
Intervention: Mesalazine granules (3 g/day, 3 g once daily or 1 g three times daily)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Mesalazine granules (3 g/day)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Mesalazine granules (once daily)
Number of subjects: 705

Group type: COMPARATOR
Intervention: Mesalazine tablets (3 g/day, 1 g three times daily)
Number of subjects: 705

Group type: COMPARATOR
Intervention: Mesalazine tablets (3 g/day)
Number of subjects: 705
Study: 20027354

Group type: EXPERIMENTAL
Intervention: Afala
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serenoa repens extract (reference preparation)
Number of subjects: 0
Study: 17099030

Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin solution with oral ciprofloxacin
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo with oral ciprofloxacin
Number of subjects: 53
Study: 14768081

Group type: EXPERIMENTAL
Intervention: Polylactic acid membrane (0.1 mm thickness)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Blank control
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Polylactic acid membrane
Number of subjects: 62
Study: 11207084

Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation of accessory pathways
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group of 100 consecutive patients with successful accessory pathway ablation without prior evidence of paroxysmal atrial fibrillation
Number of subjects: 116
Study: 9234042

Group type: EXPERIMENTAL
Intervention: Marijuana cigarettes with 3.5% THC
Number of subjects: 6

Group type: COMPARATOR
Intervention: Marijuana cigarettes with 0.0% THC
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Marijuana cigarettes with 2.0% THC
Number of subjects: 6
Study: 10147265

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 1637
Study: 3227053

Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg (single dose)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rolipram 0.75 mg (multiple dosing every 8 hours for 5 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rolipram 1.5 mg (multiple dosing every 8 hours for 5 days)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo control (single dose)
Number of subjects: 8
Study: 31853772

Group type: EXPERIMENTAL
Intervention: Access to free HIV self‐testing (ST) kits
Number of subjects: 272

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 272
Study: 30621517

Group type: EXPERIMENTAL
Intervention: Probiotic
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 28081044

Group type: EXPERIMENTAL
Intervention: Condom Barriers Scale - Partner-related barriers
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Condom Barriers Scale - Sensation-related barriers
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Condom Barriers Scale - Motivation-related barriers
Number of subjects: 600
Study: 26305186

Group type: EXPERIMENTAL
Intervention: Process-based cognitive training intervention
Number of subjects: 59

Group type: COMPARATOR
Intervention: Treatment-as-usual control condition
Number of subjects: 59
Study: 23368836

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention for youth depression through primary care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher baseline depressive symptoms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline problematic substance use
Number of subjects: 0
Study: 21401351

Group type: COMPARATOR
Intervention: Articaine (40 mL of articaine HCI 20 mg/mL with 2 mL isotonic sodium chloride solution)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Articaine-fentanyl (40 mL of articaine HCI 20 mg/mL with 2 mL (100 µg) of fentanyl)
Number of subjects: 50
Study: 18368615

Group type: EXPERIMENTAL
Intervention: Mirtazapine (15 mg nocte for 2 days, 30 mg nocte for 12 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 16988084

Group type: EXPERIMENTAL
Intervention: Tailored weight management intervention (6 monthly outpatient visits, 15 minutes each)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 144
Study: 14523770

Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 10749622

Group type: EXPERIMENTAL
Intervention: Sequential GM‐CSF/bFGF therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bFGF alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GM‐CSF/bFGF group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: bFGF
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Any cytokine treatment
Number of subjects: 0
Study: 9361572

Group type: EXPERIMENTAL
Intervention: Continuous intravenous heparin
Number of subjects: 433

Group type: COMPARATOR
Intervention: Subcutaneous heparin
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Continuous intravenous heparin for 10 days
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Continuous intravenous heparin for 5 days
Number of subjects: 433

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin
Number of subjects: 433

Group type: EXPERIMENTAL
Intervention: Pooled analysis of continuous intravenous heparin
Number of subjects: 433
Study: 1551505

Group type: EXPERIMENTAL
Intervention: iohexol-240
Number of subjects: 40

Group type: COMPARATOR
Intervention: iohexol-300
Number of subjects: 40
Study: 4037710

Group type: EXPERIMENTAL
Intervention: Primperan (30 mg per day for 15 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31210557

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) for 3 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no LGG)
Number of subjects: 64
Study: 29189318

Group type: EXPERIMENTAL
Intervention: NANCAL-guided remifentanil administration
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fixed remifentanil concentration at 4 ng/ml
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure response to NANCAL
Number of subjects: 48
Study: 26449721

Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: 20 mg amphetamine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: d-amphetamine (various doses) in mice
Number of subjects: 66

Group type: COMPARATOR
Intervention: Vehicle in mice
Number of subjects: 66
Study: 24602062

Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM)
Number of subjects: 433

Group type: COMPARATOR
Intervention: Ambulatory follow-up (Control)
Number of subjects: 433
Study: 22729167

Group type: EXPERIMENTAL
Intervention: Blephasteam eyelid‐warming device
Number of subjects: 20

Group type: COMPARATOR
Intervention: Warm compresses
Number of subjects: 20
Study: 20145560

Group type: EXPERIMENTAL
Intervention: Flexi-bar exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham-bar exercise
Number of subjects: 9
Study: 18203890

Group type: EXPERIMENTAL
Intervention: EGG group (intake of 3 eggs per day, 640 mg/d additional dietary cholesterol)
Number of subjects: 28

Group type: COMPARATOR
Intervention: SUB group (equivalent amount of egg substitute, 0 dietary cholesterol)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 16434933

Group type: EXPERIMENTAL
Intervention: Atypical neuroleptics prescribed (63.0% of patients)
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: Classic neuroleptics prescribed (49.7% of patients)
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: Association of neuroleptics (22.0% of patients)
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: Olanzapine (28.0%) and risperidone (18.6%)
Number of subjects: 1861

Group type: EXPERIMENTAL
Intervention: At least one neuroleptic treatment change (44.9% in public, 39.2% in private)
Number of subjects: 1861
Study: 12588387

Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg g(-1) ointment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Calcipotriol 50 microg g(-1) ointment
Number of subjects: 75
Study: 10735152

Group type: EXPERIMENTAL
Intervention: Novel iso-osmotic laxative
Number of subjects: 0
Study: 8671231

Group type: EXPERIMENTAL
Intervention: Simplified ultralong protocol (ULP) of gonadotrophin-releasing hormone agonist (GnRHa) with a single injection of 3.75 mg Decapeptyl followed by daily s.c. administration of 0.1 mg Decapeptyl for at least 2 weeks prior to ovarian stimulation.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Long protocol (LP) of gonadotrophin-releasing hormone agonist (GnRHa) with daily s.c. administration of 0.1 mg Decapeptyl initiated from the mid-luteal phase of the preceding cycle.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Simplified ultralong protocol (ULP) in patients with stage III or IV endometriosis.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Long protocol (LP) in patients with stage III or IV endometriosis.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Simplified ultralong protocol (ULP) in patients with stage I or II endometriosis.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Long protocol (LP) in patients with stage I or II endometriosis.
Number of subjects: 80
Study: 2003660

Group type: EXPERIMENTAL
Intervention: Standard laceration repair with music
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard laceration repair without music (control)
Number of subjects: 38
Study: 6431075

Group type: EXPERIMENTAL
Intervention: Metered 0.4 mg nitroglycerin spray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Soft gelatin capsule containing 0.8 mg nitroglycerin solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sublingual nitroglycerin tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31706331

Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (1 × 10^8 CFU, 5 drops once daily)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 114
Study: 27858723

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 26563246

Group type: EXPERIMENTAL
Intervention: Peer assessment (PA) program
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual strategy 'case discussion'
Number of subjects: 49
Study: 23514080

Group type: EXPERIMENTAL
Intervention: Higher sexual sensation seeking
Number of subjects: 715
Study: 21558772

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 160
Study: 19299240

Group type: EXPERIMENTAL
Intervention: Raloxifene continued for 8 years (RLX-C, n = 2280)
Number of subjects: 3967

Group type: EXPERIMENTAL
Intervention: Raloxifene discontinued after 4 years (RLX-D, n = 401)
Number of subjects: 3967

Group type: COMPARATOR
Intervention: Placebo (n = 1286)
Number of subjects: 3967
Study: 17540083

Group type: EXPERIMENTAL
Intervention: Counselling messages delivered immediately after consultation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Counselling messages delivered one day after consultation
Number of subjects: 55
Study: 15462490

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15669595

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) at 0.025 IU/kg/day for 1 week, increasing to 0.05 IU/kg/day for 8 weeks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH)
Number of subjects: 35

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) with normal CRP levels
Number of subjects: 35

Group type: COMPARATOR
Intervention: placebo with normal CRP levels
Number of subjects: 35
Study: 10516940

Group type: EXPERIMENTAL
Intervention: Psiquial (fluoxetine formulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Prozac (fluoxetine formulation)
Number of subjects: 24
Study: 7864430

Group type: EXPERIMENTAL
Intervention: Preoperative enalaprilat (1.25 mg intravenously [i.v.] 20 min prior to induction)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Intraoperative enalaprilat (0.625 mg i.v. at the onset of tourniquet‐associated hypertension)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1685993

Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7021140

Group type: EXPERIMENTAL
Intervention: Clonazepam (Rivotril)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Carbamazepine (Tegretol)
Number of subjects: 36
Study: 31974142

Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 3065

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3065